Free Trial

Helix BioPharma Q1 2024 Earnings Report

Helix BioPharma logo
$0.45 0.00 (0.00%)
As of 01/8/2025

Helix BioPharma EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Helix BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Helix BioPharma Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Grab these five dividend cheat sheets (Ad)

Would you like a simple set of guidelines for building a rock solid dividend portfolio? Including the two specific tickers I just put $50k into? Well, it’s all included in these FIVE Dividend Cheat Sheets

>> You can grab your FREE, laminated copies right here << 

Helix BioPharma Earnings Headlines

Helix BioPharma Appoints New CFO
Why lunchtime is primetime for smart traders
I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!
Helix BioPharma Secures U.S. Patent for Cancer Therapy
Helix BioPharma Highlights L-DOS47 at World ADC
See More Helix BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Helix BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helix BioPharma and other key companies, straight to your email.

About Helix BioPharma

Helix BioPharma (OTCMKTS:HBPCF) operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

View Helix BioPharma Profile

More Earnings Resources from MarketBeat